An Unexpected Diagnosis of COVID-19 in a Trauma Patient

Abstract

At the end of December 2019, a fast-spreading outbreak had started due to a novel coronavirus in Wuhan city of Hubei, China. At first, patients who do not meet the disease’s criteria were accepted without COVID-19 but later we noticed that even these patients may have the disease. So, during the pandemic period, every patient must be assumed to have the disease and necessary preventive measures must be taken. In this case, we unexpectedly observed COVID-19 in an old patient who admitted to the emergency department with trauma.

Keywords

• Trauma,
• Emergency,
• COVID-19

Bir Travma Hastasında Beklenmeyen COVID-19 Tanısı

Abstract

Çin’in Hubei bölgesindeki Wuhan şehrinde 2019 Aralık ayı sonunda hızlı bir şekilde yayılan bir salgın başladı. Başlangıçta hastalık kriterlerini karşılamayan hastalarda COVID-19 olmadığı kabul edildi ama daha sonra bu hastalarda bile COVID-19 olabileceğini fark edildi. Yani pandemi dönemi boyunca her hastada COVID-19 olabileceği varsayılmalı ve gerekli koruyucu önlemler alınmalıdır. Bu vakamızda, acil servise travma nedeniyle başvuran yaşlı bir hastada beklenmedik bir şekilde COVID-19 tespit ettik.

Keywords

• Travma,
• Acil,
• COVID-19

References

1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265-269.
2. Velavan TP and Meyer CG. The COVID-19 epidemic. Trop. Med. Int. Health. 2020;25(3):278-280.
3. Lai C, Shih T, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55:1-9.
4. Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology. 2020;296:E15-E25.
5. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:391-393.
6. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;20:425-434.
7. Kong W and Agarwal PP. Chest Imaging appearance of COVID-19. Infection. 2020;2(1):1-22.
8. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020;296(2):E115-117.

9. Wu Z. and McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China. Chinese Center for Disease Control and Prevention, Beijing, China. JAMA. 2020: E1-4.
10. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020:1-3.
11. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D‐dimer levels on admission to predict in‐hospital mortality in patients with COVID‐19. J Thromb Haemost. 2020;18:1324–1329.
12. Gautret P, Lagier JC, Parola P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. 2020;56(1):1-6.
13. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med. 2020;382(19):1787-1799.
14. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020; doi: 10.1101/2020.03.17.20037432
15. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br. J. Haematol. 2020;189(5):846-847.
16. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. COVID-19 in critically ıll patients in the seattle region-case series. N Engl J Med. 2020;382(21):2012-2022.